THE spring launch when he revealed "ResearchKit," a collection of iPhone apps designed to allow individuals to collect their clinical data-and contribute to the precision medicine movement-outside the conf nes of hospitals and labs. But are these simply a smattering of souped-up health apps in a sea of thousands (that is, no big deal)? Are they support tools for uncontrolled clinical trials, which won't produce meaningful results (not to mention superf uous, given that patient-centered outcomes initiatives are well under way)? Or are they precursors heralding a tectonic shif in how people participate in their health management as well as in human disease research and clinical trials? T e answer might depend more on human psychology than human health science.
App-enabled trial participation: Tectonic shift or tepid rumble?
CREDIT: BRIAN attributes for each patient, and this cluster can then serve as a personalized classif er to be used both by the participant and researchers.
T ese app-based clinical trials should not be seen as pioneering the enrollment of participant-centered trials, as many such precursors exist-such as those supported by the government agency Patient-Centered Outcomes Research Institute (PCORI), which has supported several trials primarily focused on comparing evidence-based health care options (3). What is notable, however, is the rapidity of enrollment, largely by patients who indicate a desire to share their data broadly (75%). Also exciting are the potential benef ts of shif ing beyond surveys to the collection of sensor data that can be collected both directly and frequently with little hassle to provide streams of objective phenotypic data.
NEXT-GEN APPS: ENGAGEMENT AND CONSEQUENCES
Despite some promising aspects already apparent from these ResearchKit-driven clinical app studies, there are several obvious issues to be solved. Most people who download apps use them for only short stretches of time before they get bored. Similarly, classical trials have well-known problematic issues related to patient retention (4) . ResearchKit apps will need to invent ways to o% er participants a creative experience that they can integrate into their daily lives and from which they both benef t personally and gain a sense of being a part of something larger than themselves that has the potential to helps others. Participant forums-such as chatrooms with researchers-or immediate feedback that gives, for example, a running tally of participants in one's hometown or demographic or a link to a related new scientif c paper or personal story might provide the needed push to participate.
T ere are strong selection biases among those who participate through the use of a def ned product, such as an iPhone, that will a% ect the ability to ref ect these f ndings across broad segments of populations. Furthermore, participant-centered trials have, as a core feature, the sharing of data by participants about themselves. Although there is great value in people contributing data about themselves, we anticipate that such knowledge can bias participants, causing a shif in the calculated e% ects of health modulators; this assumption is in keeping with the placebo e% ect and is a reason why double-blinded trials are popular. Psychologists have long been aware of the signif cant potential contamination when participants and researchers are not blinded to the study components (5) .
NEXT DIRECTIONS
T e use of pervasive computing devices, such as smartphones, as the vehicle with which to collect data and insights has as one of its main advantages the ability to shif away from simply collecting subjective data combined with infrequent collections of objective data. Instead, biosensors allow one to collect real-time objective data about a disease that would normally be collected within subjective assessments-such as "How would you rate your recent pain level?" (which is prone to vague recollections). As the "Internet of things" (6) (including smartphones) emerges, we can realize the power of real-time data. Before that can occur, we need to learn how to parse signal from noise and to validate these new measures.
Existing markers of disease, such as cholesterol levels and blood pressure, were developed by linking the numerical levels to disease progression. When a new candidate biomarker is developed, it also must be linked to disease progression. As with any new biomarker, the existing validated health measures that we are now capable of following with biosensors rarely have preexisting biomarker data that could be exploited to perform the needed comparisons. T is means that, for each symptom that could help drive a ResearchKit study, we will need to wait for an interval of time to pass during which we can collect both the well-validated existing measure and accompanying new sensor data to complete the so-called "validation loop. " A validation loop refers to the process of identifying a new candidate biomarker and then linking changes in the biomarker with changes in the designated disease.
Furthermore, there is the exciting but puzzling possibility that real-time measures from sensors might highlight day-to-day variations that current measures had assumed were simply noise. For example, if every text or e-mail we type can be used to track cognition f uctuations, then we might learn how we need to change our experimental designs to truly study cognition rather than using existing cognitive tests that pride themselves on their lack of being inf uenced by diurnal variations.
One approach being used in some of the ResearchKit studies is to build three-layered stacks of information that tie together (i) reasonably well validated survey questions that can only be administered infrequently with (ii) structured tasks that have a def ned activity for a short-def ned period of time and (iii) passively acquired continuous feeds of data. As an example, in the mPower app to follow Parkinson disease patients, there are infrequent surveys for tremors and movements, structured tasks such as for tapping and walking, and continuous location data feeds that provide position without divulging exact locations. T is three-layered stack of data is being used to help ground the passive and the structured-task data so that, combined, there is a better chance of making sense out of the eventually powerful feeds of continuous passive data. T is approach of linking high-friction, well-validated surveys to moderate-friction structured tasks and the inclusion of passive data streams could be used to help track a wide range of symptoms. As this practice becomes more common, there could be a powerful transition of classifying diseases by isolated symptoms as might be collected in a physician's of ce to the real-time collection of variations in daily activities that better ref ect the full dimensions of diseases when revealed by the multiple dimensions of real-time data collected from sophisticated sensors. T is advance will require the mapping of current symptoms and their paired variations in daily tasks back onto the genomic defects associated with various diseases. Such ideas will require large cohorts, some of them very well phenotyped and genotyped, and a way to navigate through the impending morass of related apps that all will vie for becoming the standards by which to follow the symptoms underlie various diseases. T e current ecosystem of academic scientists and start-up companies each hoping to build out ways to follow various symptoms is unlikely to be an ef cient way to transition to a set of standard ways to follow the diverse symptoms that def ne health and disease. T is then begs the question-what will it take to accelerate the uncovering of robust ways to track various symptoms and adoption of them as standard tools?
Currently, ResearchKit code (1) and codes for the f rst class of apps have been made available as open-source code on GitHub. Mechanisms for individuals to work as a group to build new symptom modules (such as for cognition or mood) for ResearchKit and for enticing these groups to make widely available their raw data, code, and analyses could accelerate the adoption of a standard way to assess that symptom. T ere exists a long history of nurturing such collaborations, as was done by astronomers (7) and by the SNP consortium for DNA variations (http://metadatabase.org/wiki/the_SNP_ consortium_database). Such "federated" approaches to developing new symptom modules could be very ef cient but would need to somehow be nurtured by interested parties, possibly including funders and participants.
ULTIMATE ECOSYSTEM
As we anticipate a world in which data and insights surrounding aspects of our health and disease become more available through the use of pervasive computers and the "Internet of things, " it is likely that there can be one further acceleration in the existing biomedical paradigm. E% orts in translational medicine have primarily been driven by a linear process of designing a study to ask a pertinent question about health and disease, f nding someone who will fund one's e% orts to generate the ideas, analyzing the data, and publishing the f ndings so another person can take a turn on the crank. Long delays are possible at each stage, but the dominant one is that we assume that most data are generated for the question being asked. When this kind of delay applies to a longitudinal study, the turn of the crank could be measured in years to decades. T e use of real-time sensor data that can be mapped onto symptoms collected among individuals and that go beyond being condensed into standard, well-def ned signs and symptoms means that one might be able to analyze biomedical data as if each of our lives were continuous longitudinal studies. If the accumulation of data were consented by app-driven participant-centered trials so that the resulting body of data was available to qualif ed researchers worldwide, then the time it takes to iterate and discuss new ideas might become equivalent to the time required to perform analysis of the data.
Recognizing the wisdom of Yogi Berra's saying, "It's tough to make predictions, especially about the future," I'll bet that real-time streaming of data from pervasive computing devices, as has been shown possible through the participant-driven trials enabled by the ResearchKit apps, may be equally poised to impact precision medicine as the e% orts to make legacy medical records interoperable.
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